Investment
Features
FeesSafety
Academy
More
Pluang+

Compare VanEck JP Morgan EM Local Currency Bond ETF (EMLC) vs Sanofi SA (SNY) Price & Performance

VanEck JP Morgan EM Local Currency Bond ETFTrade
Sanofi SATrade

Price performance (Past 24H)

Key statistics

VanEck JP Morgan EM Local Currency Bond ETF vs Sanofi SA — how do they compare? VanEck JP Morgan EM Local Currency Bond ETF trades at $25.47, while Sanofi SA trades at $44.19 (market cap $103.94B). The key difference: Sanofi SA pays a 5.54% dividend while VanEck JP Morgan EM Local Currency Bond ETF pays none, and VanEck JP Morgan EM Local Currency Bond ETF is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.

EMLCSNY
Sector
Fixed IncomeHealth
52-Week High
$26.59$52.34
52-Week Low
$24.83$41.33
Market Cap
$103.94B
Enterprise Value
$120.43B
Dividend Yield
5.54%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

VanEck JP Morgan EM Local Currency Bond ETF

EMLC trades at $25.47, showing minimal daily movement with a slight decline of 0.04%. Technical indicators signal a bullish trend with moving averages supporting upward momentum, while oscillators remain neutral. The ETF maintains consistent dividend payments of $0.14 per share throughout 2026, providing steady income. Recent news highlights growing institutional interest in emerging market bonds as investors seek yield above Treasury rates.

The outlook for EMLC appears favorable given the Federal Reserve's accommodative stance and emerging market debt's attractive yield premium. However, currency risk and capital erosion concerns persist as short interest has surged 73%, indicating skepticism about long-term sustainability despite the 6.1% trailing yield.

Sanofi SA

Sanofi (SNY) trades at $44.11, up 2.15% today, with a bullish technical signal supported by moving averages. The company shows strong fundamentals with a P/E of 19.37, net income margin of 15.95%, and consistent earnings beats in recent quarters. Recent FDA approval for Sarclisa's subcutaneous formulation and EU clearance for Cenrifki highlight pipeline progress, while a dividend of $2.42 per share underscores shareholder returns.

Outlook remains positive driven by Dupixent growth and new drug approvals, though risks include EU antitrust probes and competitive pressures. Analysts are mixed with 44% buy ratings, suggesting cautious optimism. The stock presents value with solid cash flow and profitability, but investors should monitor regulatory developments and pipeline execution for sustained upside.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About VanEck JP Morgan EM Local Currency Bond ETF

EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.

Read more on EMLC

About Sanofi SA

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Read more on SNY